Welcome on board!

Company overview

Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying.

Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s lead assets originated from the Pleotherapy R&D approach.

˪ Disclosure of the total number of voting rights and shares composing the share capital


Total number of shares composing the share capital

August 31, 2023

3 909 336 626 (1)

(1)  This table will be subject to a monthly update of (i) the number of shares issued from the convertible bond program announced on June 7, 2021, with Global Tech Opportunities 13, and (ii) the OBSA program announced on October 3, 2022 with Equitis Gestion (a management trust set up by Néovacs), detailed in follow-up tables available HERE

˪ Stock information

Stock Market

Euronext Growth Paris







Closing date

31 December

First day of trading

18 July 2016

Number of shares

See table above


EnterNext© PEA-PME 150,

Euronext Growth All-Share, Next Biotech, PEA

Liquidity contract

Kepler Cheuvreux

Eligible to PEA-PME (French fiscal advantage)

Share price

Analysts coverage

The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.

General meeting (only available in French)
˪ For investors
Pharnext Headquarters

9 rue des Filles Saint-Thomas

75002 Paris, France

+33 (0)1 41 09 22 30
Investors relation (France)
ACTUS finance & communication

Jérôme Fabreguettes Leib

+33 (0)1 53 67 36 78
˪ For media
Pharnext Headquarters

9 rue des Filles Saint-Thomas

75002 Paris

+33 (0)1 41 09 22 30
Financial Press Relation (France)
ACTUS finance & communication

Déborah Schwartz
+33 (0)1 53 67 36 35
Next step